Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gen-Probe Prepares For West Nile Virus Test Commercial Uptake

This article was originally published in The Gray Sheet

Executive Summary

Gen-Probe expects an upsurge in revenue from its West Nile Virus blood screening assay shortly after FDA approval, according to CFO and VP-Finance Herm Rosenman

You may also be interested in...



Gen-Probe Aims For Long-Term Growth With Oncological Assays

Gen-Probe will continue to devote a quarter of its revenue to research and development in anticipation of entering the oncology and industrial testing markets

Gen-Probe Aims For Long-Term Growth With Oncological Assays

Gen-Probe will continue to devote a quarter of its revenue to research and development in anticipation of entering the oncology and industrial testing markets

Gen-Probe Cultivates Cancer Segment Through Roche HPV DNA Probe Deal

A supply and purchase agreement with Roche Molecular Systems for human papillomavirus DNA probes could enable Gen-Probe's fledgling oncology segment to introduce an HPV diagnostic in the U.S. by 2009, CEO Henry Nordhoff stated

Related Content

UsernamePublicRestriction

Register

MT022268

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel